Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - telmisartan, quantity: 40 mg - tablet, uncoated - excipient ingredients: sodium hydroxide; meglumine; lactose; magnesium stearate; povidone; lactose monohydrate; crospovidone - noumed telmisartan is indicated for - treatment of hypertension - prevention of cardiovascular morbidity and mortality in patients 55 years or older with coronary artery disease, peripheral artery disease, previous stroke, transient ischaemic attack or high risk diabetes with evidence of end organ damage (see clinical trials)

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - simvastatin, quantity: 40 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; citric acid monohydrate; lactose monohydrate; purified talc; ascorbic acid; hypromellose; pregelatinised maize starch; butylated hydroxyanisole; titanium dioxide; iron oxide red; magnesium stearate - adjunct to diet for treatment of hypercholesterolaemia.prior to initiating therapy with noumed simvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. noumed simvastatin is indicated in patients at high risk of coronary heart disease (chd) (with or without hypercholesterolaemia) including patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd to reduce the risk of cardiovascular death, major cardiovascular events including stroke, and hospitalisation due to angina pectoris.these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - simvastatin, quantity: 20 mg - tablet, film coated - excipient ingredients: magnesium stearate; iron oxide yellow; titanium dioxide; citric acid monohydrate; purified talc; ascorbic acid; lactose monohydrate; hypromellose; microcrystalline cellulose; pregelatinised maize starch; iron oxide red; butylated hydroxyanisole - adjunct to diet for treatment of hypercholesterolaemia.prior to initiating therapy with noumed simvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. noumed simvastatin is indicated in patients at high risk of coronary heart disease (chd) (with or without hypercholesterolaemia) including patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd to reduce the risk of cardiovascular death, major cardiovascular events including stroke, and hospitalisation due to angina pectoris.these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - simvastatin, quantity: 10 mg - tablet, film coated - excipient ingredients: citric acid monohydrate; lactose monohydrate; titanium dioxide; ascorbic acid; hypromellose; purified talc; microcrystalline cellulose; iron oxide yellow; pregelatinised maize starch; iron oxide red; magnesium stearate; butylated hydroxyanisole - adjunct to diet for treatment of hypercholesterolaemia.prior to initiating therapy with noumed simvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. noumed simvastatin is indicated in patients at high risk of coronary heart disease (chd) (with or without hypercholesterolaemia) including patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd to reduce the risk of cardiovascular death, major cardiovascular events including stroke, and hospitalisation due to angina pectoris.these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - terbinafine hydrochloride, quantity: 281.31 mg (equivalent: terbinafine, qty 250 mg) - tablet, uncoated - excipient ingredients: magnesium stearate; sodium starch glycollate type a; purified talc; microcrystalline cellulose; colloidal anhydrous silica; hypromellose - treatment in adults of ringworm (tinea corporis, tinea cruris and tinea pedis) due to infection caused by dermatophytes such as trichophyton (e.g. t. rubrum, t. mentagrophytes, t. verrucosum, t. violaceum), microsporum canis and epidermophyton floccosum, where oral therapy is considered appropriate owing to the site, severity or extent of the infection, and the infection is not responsive to topical therapy. onychomycosis in adults (fungal infection of the nail) caused by dermatophyte fungi.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - sertraline hydrochloride, quantity: 111.9 mg (equivalent: sertraline, qty 100 mg) - tablet, film coated - excipient ingredients: sodium starch glycollate; calcium hydrogen phosphate dihydrate; purified talc; hypromellose; magnesium stearate; microcrystalline cellulose; hyprolose; titanium dioxide - treatment of children (aged 6 years and older) and adolescents with obsessive compulsive disorder. treatment of major depression, obsessive compulsive disorder and panic disorder in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - sertraline hydrochloride, quantity: 55.95 mg (equivalent: sertraline, qty 50 mg) - tablet, film coated - excipient ingredients: titanium dioxide; calcium hydrogen phosphate dihydrate; purified talc; microcrystalline cellulose; hypromellose; hyprolose; sodium starch glycollate; magnesium stearate - treatment of children (aged 6 years and older) and adolescents with obsessive compulsive disorder. treatment of major depression, obsessive compulsive disorder and panic disorder in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - citalopram hydrobromide, quantity: 49.98 mg (equivalent: citalopram, qty 40 mg) - tablet, film coated - excipient ingredients: sodium starch glycollate; hypromellose; maize starch; lactose monohydrate; purified talc; microcrystalline cellulose; glycerol; macrogol 6000; magnesium stearate; titanium dioxide; copovidone - treatment of major depression.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - citalopram hydrobromide, quantity: 24.99 mg (equivalent: citalopram, qty 20 mg) - tablet, film coated - excipient ingredients: maize starch; microcrystalline cellulose; glycerol; hypromellose; titanium dioxide; lactose monohydrate; sodium starch glycollate; magnesium stearate; copovidone; purified talc; macrogol 6000 - treatment of major depression.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - fluoxetine hydrochloride, quantity: 22.4 mg (equivalent: fluoxetine, qty 20 mg) - capsule, hard - excipient ingredients: titanium dioxide; iron oxide yellow; dimeticone 350; gelatin; patent blue v; pregelatinised maize starch - treatment of major depression. treatment of obsessive compulsive disorder (ocd). treatment of major depression. treatment of obsessive compulsive disorder (ocd).